# TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

> **NCT03615144** · PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Non-Malignant Hematologic Disorders

## Interventions

- **DRUG:** Melphalan
- **DRUG:** Thiotepa
- **DRUG:** Clofarabine
- **DRUG:** Fludarabine
- **DRUG:** Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
- **PROCEDURE:** CliniMACS reagents

## Key facts

- **NCT ID:** NCT03615144
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-23
- **Primary completion:** 2020-11-13
- **Final completion:** 2020-11-13
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Participant accrual low and the study was closed
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03615144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03615144, "TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03615144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*